MiR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma

Oncology Reports

Volumn 33, Issue 2, 2015, Pages 713-720

  Feng, Jiye ^a   Wang, Jinbo ^a   Chen, Mingliang ^a   Chen, Gun ^a   Wu, Zongyang ^a   Ying, Liping ^a   Zhuo, Qifeng ^a   Zhang, Jianlei ^a   Wang, Weilin ^b  

^a NINGBO UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Hepatocellular carcinoma; MACC1; MiR 200a; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; MICRORNA 200A; MACC1 PROTEIN, HUMAN; MICRORNA; MIRN200 MICRORNA, HUMAN; TRANSCRIPTION FACTOR;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MACC1 GENE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CANCER; OVERALL SURVIVAL; TUMOR GROWTH; TUMOR INVASION; TUMOR RECURRENCE; TUMOR VOLUME; AGED; CELL MOTION; CELL PROLIFERATION; GENETICS; HEPG2 CELL LINE; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 84919460487     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3642     Document Type: Article

References (35)

1. Shiraha H, Yamamoto K and Namba M: Human hepatocyte carcinoGenesis (Review). Int J Oncol 42: 1133-1138, 2013.
2. Finn RS: Emerging targeted strategies in advanced hepato-cellular carcinoma. Semin Liver Dis 33 (Suppl 1): S11-S19, 2013.
3. Whittaker S, Marais R and Zhu AX: The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29: 4989-5005, 2010.
4. Carr BI: Some new approaches to the management of hepato-cellular carcinoma. Semin Oncol 39: 369-373, 2012.
5. Hamed O, Kimchi ET, Sehmbey M, Gusani NJ, Kaif JT and Staveley-O'Carroll K: Impact of genetic targets on cancer therapy: hepatocellular cancer. Adv Exp Med Biol 779: 67-90, 2013.
6. Marrero JA: Multidisciplinary management of hepatocellular carcinoma: where are we today? Semin Liver Dis 33 (Suppl 1): S3-S10, 2013.
7. Alves RC, Alves D, Guz B, Matos C, Viana M, Harriz M, Terrabuio D, Kondo M, Gampel O and Polletti P: Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepatol 10: 21-27, 2011.
8. Herszényi L and Tulassay Z: Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 14: 249-258, 2010.
9. Hussain SA, Ferry DR, El-Gazzaz G, Mirza DF, James ND, McMaster P and Kerr DJ: Hepatocellular carcinoma. Ann Oncol 12: 161-172, 2001.
10. Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL and Inoue M: Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 21: 401-416, 2011.
11. El-Serag HB: Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35 (5 Suppl 2): S72-S78, 2002.
12. Lai EC and Lau WY: The continuing challenge of hepatic cancer in Asia. Surgeon 3: 210-215, 2005.
13. Yuen MF, Hou JL and Chutaputti A; Asia Pacifc Working Party on Prevention of Hepatocellular Carcinoma: Hepatocellular carcinoma in the Asia pacifc region. J Gastroenterol Hepatol 24: 346-353, 2009.
14. Grossman EJ and Millis JM: Liver transplantation for non-hepa-tocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature. Liver Transpl 16: 930-942, 2010.
15. Kaido T, Mori A, Ogura Y, Hata K, Yoshizawa A, Iida T and Uemoto S: Living donor liver transplantation for recurrent hepato-cellular carcinoma after liver resection. Surgery 151: 55-60, 2012.
16. Ambros V, Bartel B, Bartel D P, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, Griffths-Jones S, Marshall M, Matzke M, Ruvkun G and Tuschl T: A uniform system for microRNA annotation. RNA 9: 277-279, 2003.
17. Iorio MV and Croce CM: microRNA involvement in human cancer. CarcinoGenesis 33: 1126-1133, 2012.
18. Schetter AJ and Harris CC: Alterations of microRNAs contribute to colon carcinoGenesis. Semin Oncol 38: 734-742, 2011.
19. Chen Y, Zhang L and Hao Q: Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profling studies and experimental validation. Cancer Cell Int 13: 86, 2013.
20. Feng B, Wang R and Chen LB: Review of miR-200b and cancer chemosensitivity. Biomed Pharmacother 66: 397-402, 2012.
21. Yao J, Zhou E, Wang Y, Xu F, Zhang D and Zhong D: microRNA-200a inhibits cell proliferation by targeting mito-chondrial transcription factor A in breast cancer. DNA Cell Biol 33: 291-300, 2014.
22. Cong N, Du P, Zhang A, Shen F, Su J, Pu P, Wang T, Zjang J, Kang C and Zhang Q: Downregulated microRNA-200a promotes EMT and tumor growth through the wnt/β-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma. Oncol Rep 29: 1579-1587, 2013.
23. Kobayashi M, Salomon C, Tapia J, Illanes SE, Mitchell MD and Rice GE: Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J Transl Med 12: 4, 2014.
24. Lam SS, Mak AS, Yam JW, Cheung AN, Ngan HY and Wong AS: Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells. Mol Ther 22: 743-751, 2014.
25. Liu L, Zou J, Wang Q, Yin FQ, Zhang W and Li L: Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer. Tumour Biol 35: 7713-7717, 2014.
26. Lu Y, Lu J, Li X, Zhu H, Fan X, Zhu S, Wang Y, Guo Q, Wang L, Huang Y, Zhu M and Wang Z: MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell. BMC Cancer 14: 85, 2014.
27. Sun Q, Zou X, Zhang T, Shen J, Yin Y and Xiang J: The role of miR-200a in vasculogenic mimicry and its clinical signifcance in ovarian cancer. Gynecol Oncol 132: 730-738, 2014.
28. Banyard J, Chung I, Wilson AM, Vetter G, Le Béchec A, Bielenberg DR and Zetter BR: Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. Sci Rep 3: 3151, 2013.
29. Cao Q, Lu K, Dai S, Hu Y and Fan W: Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer. Int J Clin Exp Pathol 7: 2392-2401, 2014.
30. Kolesnikoff N, Attema JL, Roslan S, Bert AG, Schwarz QP, Gregory PA and Goodall GJ: Specificity protein 1 (Sp1) maintains basal epithelial expression of the miR-200 family: implications for epithelial-mesenchymal transition. J Biol Chem 289: 11194-11205, 2014.
31. Koutsaki M, Spandidos DA and Zaravinos A: Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics. Cancer Lett 351: 173-181, 2014.
32. Song FI, Yang D, Liu B, Guo Y, Zheng H, Li L, Wang T, Yu J, Zhao Y, Niu R, Liang H, Winkler H, Zhang W, Hao X and Chen K: Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin Cancer Res 20: 878-889, 2014.
33. Truong HH, Xiong J, Ghotra VP, Nirmala E, Haazen L, Le Dévédec SE, Balcioglu HE, He S, Snaar-Jagalska BE, Vreugdenhil E, Meerman JH, Van de Water B and Danen EH: β1 integrin inhibition elicits a prometastatic switch through the TGFβ-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer. Sci Signal 7: ra15, 2014.
34. Wang CH, Chen CL, More SV, Hsiao PW, Hung WC and Li WS: The tetraindole SK228 reverses the epithelial-to-mesenchymal transition of breast cancer cells by up-regulating members of the miR-200 family. PLoS One 9: e101088, 2014.
35. Wang CM, Liu R, Wang L, Nascimento L, Brennan VC and Yang WH: SUMOylation of FOXM1B alters its transcriptional activity on regulation of miR-200 family and JNK1 in MCF7 human breast cancer cells. Int J Mol Sci 15: 10233-10251, 2014.